Summary of study ST001226

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000822. The data can be accessed directly via it's Project DOI: 10.21228/M8F69D This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Download all metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST001226
Study TitleAquamin and Prevention of Colon Cancer (part-II)
Study TypeMS analysis
Study SummaryWe propose to evaluate microbial and metabolic profiles in baseline and endpoint colonic mucosal, fecal, and serum samples from human patients at risk for CRC and enrolled in a 90-day phase I clinical trial. Patients will receive daily supplementation with calcium alone, a calcium-rich multimineral (Aquamin?), or placebo (maltodextrin) (n=10 per group). We hypothesize that dietary supplementation will correlate with CRC-protective metabolic profiles and that multimineral supplementation will generate more favorable profiles than calcium supplementation alone.
Institute
University of Michigan
DepartmentBiomedical Research Core Facilities
LaboratoryMetabolomics core
Last NameKachman
First NameMaureen
AddressAnn Arbor, MI
Emailmkachman@med.umich.edu
Phone734-232-0842
Submit Date2019-07-23
Num Groups24
Total Subjects18
Study CommentsColorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer related death when both genders are combined. Epidemiologically, calcium intake has been protective against colonic adenomas and even colon cancer. Calcium supplementation has reduced the risk of colon adenoma formation in subjects with a history of previous colon polyps. The utility of calcium supplementation for colon cancer prevention is somewhat modulated by the modest or inconsistent level of protection afforded. Our preliminary data in mice and human enterocyte models shows that dietary supplementation with a multimineral supplement (Aquamin?) containing calcium in combination with 72 measureable trace minerals is more protective against tumors and epithelial growth dysregulation than calcium alone. One potential mechanism, supported by our rodent data, is that multimineral supplementation alters gut microbial populations to generate bile acid and short chain fatty acid (SCFA) profiles that are CRC-protective.
Raw Data AvailableYes
Raw Data File Type(s).m
Analysis Type DetailLC-MS
Release Date2019-09-23
Release Version1
Maureen Kachman Maureen Kachman
https://dx.doi.org/10.21228/M8F69D
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR000822
Project DOI:doi: 10.21228/M8F69D
Project Title:Aquamin and Prevention of Colon Cancer
Project Type:MS analysis
Project Summary:Effects of calcium and multi-mineral supplementation on gut microbes and microbially-derived metabolites in patients at risk for colon cancer
Institute:University of Michigan
Department:Pathology
Laboratory:Aslam Lab
Last Name:Aslam
First Name:Muhammad Nadeem
Address:Ann Arbor, MI
Email:mnaslam@umich.edu
Phone:734-936-1897

Subject:

Subject ID:SU001293
Subject Type:HUMAN
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: HUMAN; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Time Point
SA086897S00031813Baseline
SA086898S00031811Baseline
SA086899S00031810Baseline
SA086900S00031814Baseline
SA086901S00031815Baseline
SA086902S00031799Baseline
SA086903S00031816Baseline
SA086904S00031809Baseline
SA086905S00031812Baseline
SA086906S00031803Baseline
SA086907S00031802Baseline
SA086908S00031808Baseline
SA086909S00031800Baseline
SA086910S00031804Baseline
SA086911S00031801Baseline
SA086912S00031805Baseline
SA086913S00031806Baseline
SA086914S00031807Baseline
SA086915S00031830Day 90
SA086916S00031828Day 90
SA086917S00031829Day 90
SA086918S00031831Day 90
SA086919S00031833Day 90
SA086920S00031827Day 90
SA086921S00031834Day 90
SA086922S00031832Day 90
SA086923S00031817Day 90
SA086924S00031820Day 90
SA086925S00031819Day 90
SA086926S00031818Day 90
SA086927S00031821Day 90
SA086928S00031822Day 90
SA086929S00031825Day 90
SA086930S00031824Day 90
SA086931S00031823Day 90
SA086932S00031826Day 90
Showing results 1 to 36 of 36

Collection:

Collection ID:CO001287
Collection Summary:Not available.
Sample Type:Blood (serum)

Treatment:

Treatment ID:TR001308
Treatment Summary:Not available.

Sample Preparation:

Sampleprep ID:SP001301
Sampleprep Summary:Two-step solvent extraction. Supernatants are combined, dried, and re-suspended for LCMS separation by RPLC and measurements by ESI- QQQ MRM methods. Analytes are reported as uM, and CV's are generally <15%.
Sampleprep Protocol Filename:Bile_acids_analysis.doc

Combined analysis:

Analysis ID AN002039
Analysis type MS
Chromatography type Reversed phase
Chromatography system Agilent 1260
Column Waters Acquity BEH C18 (50 x 2mm, 1.7um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Agilent 6490 QQQ
Ion Mode POSITIVE
Units uM

Chromatography:

Chromatography ID:CH001479
Methods Filename:2014-07-30-Bile_acid-full-BEH-C18-I.m.zip
Instrument Name:Agilent 1260
Column Name:Waters Acquity BEH C18 (50 x 2mm, 1.7um)
Chromatography Type:Reversed phase

MS:

MS ID:MS001891
Analysis ID:AN002039
Instrument Name:Agilent 6490 QQQ
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:NA
Ion Mode:POSITIVE
  logo